CollPlant Biotechnologies Ltd. (CLGN)

CollPlant Biotechnologies Ltd. (CLGN) Healthcare & Pipeline Overview

CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company leveraging its proprietary plant-based recombinant human collagen technology to develop and commercialize 3D bioprinted tissues and organs, dermal fillers, and soft tissue repair products, primarily in the United States, Canada, and Europe.

What Is the Investment Thesis for CLGN?

CollPlant Biotechnologies presents a compelling, albeit high-risk, investment opportunity within the regenerative medicine sector. The company's proprietary rhCollagen technology offers a potential competitive advantage in the development of 3D bioprinted tissues and organs, as well as aesthetic medicine products. Key value drivers include successful clinical trials for its lead products, strategic partnerships with major players in the healthcare industry, and expansion into new geographic markets. The company's gross margin of 26.3% indicates potential for profitability as product commercialization scales. However, the company's negative profit margin of -484.6% highlights the significant R&D and operational expenses associated with its stage of development. Investors should closely monitor the company's cash burn rate and ability to secure additional funding to support its long-term growth strategy. Upcoming clinical trial results and regulatory approvals will be critical catalysts for the stock.

Based on FMP financials and quantitative analysis

CLGN Key Highlights

• CollPlant Biotechnologies focuses on regenerative and aesthetic medicine, a high-growth area within healthcare.
• The company's proprietary plant-based rhCollagen technology offers a potential competitive advantage in terms of scalability and consistency.
• Gross margin of 26.3% demonstrates the potential for profitable commercialization of its products.
• Strategic collaborations with companies like 3D Systems, CellInk, AbbVie and STEMCELL validate the potential of its technology and provide access to resources and expertise.
• The company's diverse product pipeline targets multiple high-value markets, including 3D bioprinting, wound care, and aesthetic medicine.

Who Are CLGN's Competitors?

CLGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CLGN's Key Strengths?

• Proprietary rhCollagen technology platform
• Strategic collaborations with industry leaders
• Diverse product pipeline targeting multiple markets
• Established brand recognition for Vergenix products

What Are CLGN's Weaknesses?

• Negative profit margin and high operating expenses
• Reliance on strategic partnerships for product development and commercialization
• Limited commercial infrastructure and sales force
• Dependence on regulatory approvals for product launches

What Could Drive CLGN Stock Higher?

• Clinical trial results for 3D bioprinted breast implants.
• Regulatory approvals for Vergenix products in new markets.
• Progress in strategic collaborations with AbbVie and other partners.
• Publication of research on rhCollagen technology.
• Expansion of commercial infrastructure and sales force.

What Are the Key Risks for CLGN?

• Financial-distress signal — its Altman Z-Score of -23.12 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Competition from companies developing alternative collagen sources.
• Regulatory hurdles and delays in product approvals.
• Failure of clinical trials or product recalls.
• Dependence on strategic partnerships for product development and commercialization.
• Economic downturn or changes in healthcare reimbursement policies.

What Are the Growth Opportunities for CLGN?

• Expansion of 3D Bioprinting Capabilities: CollPlant has the opportunity to expand its 3D bioprinting capabilities through strategic partnerships and internal development. The market for 3D bioprinted tissues and organs is projected to reach billions of dollars in the coming years, driven by the potential to address organ shortages and improve patient outcomes. By focusing on specific applications, such as breast implants and soft tissue matrices, CollPlant can establish a leadership position in this emerging field. The timeline for significant revenue generation depends on regulatory approvals and successful clinical trials, but initial commercialization could begin within the next 3-5 years.
• Commercialization of Vergenix Products: CollPlant's VergenixSTR and VergenixFG products represent near-term growth opportunities in the soft tissue repair and wound care markets. These products address significant unmet needs in the treatment of tendinopathy and chronic wounds, respectively. The global wound care market is estimated to be worth over $20 billion, providing a substantial market opportunity for VergenixFG. Successful commercialization will depend on effective marketing and distribution strategies, as well as positive clinical outcomes. Revenue growth from Vergenix products is expected to contribute to the company's overall financial performance within the next 1-2 years.
• Development of Aesthetic Medicine Products: CollPlant's dermal filler and soft tissue filler products target the growing aesthetic medicine market. The global market for dermal fillers is projected to reach billions of dollars, driven by increasing demand for non-invasive cosmetic procedures. By leveraging its rhCollagen technology, CollPlant can develop differentiated products with improved safety and efficacy profiles. The company's collaboration with AbbVie in this area provides access to significant resources and expertise. Commercialization of aesthetic medicine products is expected to contribute to revenue growth in the medium term, with potential for significant upside if the collaboration with AbbVie is successful.
• Strategic Partnerships and Collaborations: CollPlant's strategy of forming strategic partnerships and collaborations is crucial for its long-term growth. By partnering with industry leaders such as 3D Systems, CellInk, AbbVie and STEMCELL, the company can access resources, expertise, and distribution channels that would otherwise be unavailable. These partnerships also validate the potential of CollPlant's technology and increase its visibility within the industry. The company should continue to actively pursue new partnerships to expand its reach and accelerate its growth trajectory. The impact of these partnerships on revenue will vary depending on the specific terms and timelines of each agreement.
• Geographic Expansion: CollPlant currently focuses on the United States, Canada, and Europe. Expanding into new geographic markets, such as Asia-Pacific and Latin America, represents a significant growth opportunity. These regions have large and growing populations with increasing demand for regenerative and aesthetic medicine products. However, geographic expansion will require significant investment in regulatory approvals, marketing, and distribution infrastructure. The timeline for successful geographic expansion will depend on the specific market and the company's ability to navigate local regulations and cultural differences. Revenue from new geographic markets is expected to contribute to long-term growth.

What Opportunities Does CLGN Have?

• Expansion of 3D bioprinting capabilities
• Commercialization of Vergenix products in new markets
• Development of new aesthetic medicine products
• Acquisition of complementary technologies or businesses

What Threats Does CLGN Face?

• Competition from companies developing alternative collagen sources
• Regulatory hurdles and delays in product approvals
• Failure of clinical trials or product recalls
• Economic downturn or changes in healthcare reimbursement policies

What Are CLGN's Competitive Advantages?

• Proprietary rhCollagen Technology: CollPlant's plant-based rhCollagen technology provides a competitive advantage in terms of scalability, consistency, and purity.
• Strategic Partnerships: Collaborations with industry leaders such as 3D Systems, CellInk, AbbVie and STEMCELL enhance the company's capabilities and market reach.
• Diverse Product Pipeline: A broad portfolio of products targeting multiple high-value markets reduces reliance on any single product or application.
• Established Brand: The Vergenix brand has gained recognition in the wound care and tissue repair markets.

What Does CLGN Do?

Founded in 2004 and headquartered in Rehovot, Israel, CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company focused on developing and commercializing innovative products based on its recombinant type I human collagen (rhCollagen) produced using its proprietary plant-based genetic engineering technology. This technology allows for the production of high-quality, consistent, and scalable rhCollagen, which serves as the foundation for the company's diverse product pipeline. CollPlant's portfolio includes BioInks for 3D printing of tissues and organs, dermal fillers and soft tissue fillers for treating wrinkles, 3D Bioprinted breast implants for regeneration of breast tissue, injectable implants to promote breast tissue regeneration, and 3D bioprinted regenerative soft tissue matrix. The company also markets VergenixSTR, a soft tissue repair matrix for tendinopathy, and VergenixFG, an advanced wound care product for treating deep surgical incisions, diabetic ulcers, and other chronic wounds. CollPlant has established strategic collaborations with industry leaders such as 3D Systems Corporation, CellInk (a BICO Group company), AbbVie and STEMCELL, to further develop and commercialize its technologies. Formerly known as CollPlant Holdings Ltd., the company rebranded to CollPlant Biotechnologies Ltd. in June 2019 to better reflect its focus on biotechnology and regenerative medicine.

What Products and Services Does CLGN Offer?

• Develops recombinant type I human collagen (rhCollagen) using plant-based genetic engineering.
• Creates BioInks for 3D printing of tissues and organs.
• Produces dermal fillers and soft tissue fillers for treating wrinkles.
• Develops 3D bioprinted breast implants for breast tissue regeneration.
• Offers injectable implants to promote breast tissue regeneration.
• Manufactures 3D bioprinted regenerative soft tissue matrix.
• Markets VergenixSTR for soft tissue repair in tendinopathy treatment.
• Provides VergenixFG, an advanced wound care product for various wounds.

How Does CLGN Make Money?

• Develops and manufactures products based on its proprietary rhCollagen technology.
• Commercializes products through direct sales and distribution partnerships.
• Generates revenue from sales of BioInks, dermal fillers, wound care products, and other regenerative medicine products.
• Collaborates with other companies to develop and commercialize new products and applications.

What Industry Does CLGN Operate In?

CollPlant Biotechnologies operates within the rapidly evolving regenerative medicine and aesthetic medicine markets. The regenerative medicine market is driven by the increasing prevalence of chronic diseases, aging populations, and advancements in biotechnology. The aesthetic medicine market is fueled by growing consumer demand for minimally invasive cosmetic procedures. CollPlant's rhCollagen technology positions it to capitalize on these trends by providing a versatile platform for developing innovative products in both areas. Competition includes companies developing alternative collagen sources, 3D bioprinting technologies, and dermal fillers.

Who Are CLGN's Key Customers?

• Hospitals and clinics using Vergenix products for wound care and tissue repair.
• Aesthetic medicine practitioners using dermal fillers and soft tissue fillers.
• Research institutions and pharmaceutical companies using BioInks for 3D bioprinting.
• Patients seeking regenerative medicine solutions for various conditions.

FY2026 estForward Outlook

Wall Street analysts project CollPlant Biotechnologies Ltd. revenue of about $2.0M for fiscal 2026, with EPS near $-0.59.

F-Score 1/9Financial Health

CollPlant Biotechnologies Ltd.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -23.12 places it in the distress zone, a signal of elevated financial risk.

CollPlant Biotechnologies Ltd. (CLGN) Valuation Context

Valued at $4.89M, CLGN is classified as a micro-cap stock. Relative to its peer group, CLGN's quantitative score of 48/100 is below the peer average of 76/100.

CLGN Revenue & Earnings Trend

In Q1 2026, CLGN generated $73K in top-line revenue, marking a sequential increase of 21.7%. The company recorded a net loss of $3.1M, with diluted EPS of $-0.23. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CLGN averaged $-0.26 in diluted EPS.

Company Profile

CollPlant Biotechnologies Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Rehovot, IL. The company is led by CEO Yehiel Tal. CLGN has traded publicly since 2018.

CLGN Financials

CLGN Latest News

CLGN Analyst Consensus

CLGN MoonshotScore

Common Questions About CLGN (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources